Press coverage about Tesaro (NASDAQ:TSRO) has been trending somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tesaro earned a daily sentiment score of 0.04 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.0333851657094 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
Shares of TSRO traded down $1.76 on Friday, reaching $54.70. The company’s stock had a trading volume of 1,499,911 shares, compared to its average volume of 843,683. The company has a debt-to-equity ratio of 1.75, a current ratio of 4.74 and a quick ratio of 4.39. Tesaro has a twelve month low of $52.20 and a twelve month high of $168.92. The firm has a market capitalization of $3,080.68, a PE ratio of -5.97 and a beta of 1.34.
Tesaro (NASDAQ:TSRO) last posted its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.39) by ($0.96). The business had revenue of $48.02 million during the quarter, compared to analyst estimates of $51.78 million. Tesaro had a negative return on equity of 126.44% and a negative net margin of 222.15%. analysts expect that Tesaro will post -9.46 EPS for the current year.
Several brokerages have recently issued reports on TSRO. HC Wainwright reiterated a “buy” rating and set a $108.00 price target on shares of Tesaro in a report on Tuesday, March 27th. BidaskClub raised shares of Tesaro from a “strong sell” rating to a “sell” rating in a research report on Tuesday, March 6th. Credit Suisse Group reaffirmed an “in-line” rating and set a $141.00 price target (down previously from $150.00) on shares of Tesaro in a research report on Wednesday, February 28th. Wells Fargo reaffirmed an “outperform” rating and set a $122.00 price target (down previously from $224.00) on shares of Tesaro in a research report on Wednesday, February 28th. Finally, ValuEngine raised shares of Tesaro from a “sell” rating to a “hold” rating in a research report on Friday, March 2nd. One analyst has rated the stock with a sell rating, eleven have given a hold rating and fourteen have issued a buy rating to the company. Tesaro has an average rating of “Buy” and an average price target of $129.26.
In other news, major shareholder Peter J. Barris acquired 145,532 shares of the firm’s stock in a transaction on Tuesday, March 6th. The stock was purchased at an average price of $57.40 per share, for a total transaction of $8,353,536.80. Following the purchase, the insider now owns 252 shares in the company, valued at approximately $14,464.80. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Grant C. Bogle sold 1,809 shares of the stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $54.85, for a total transaction of $99,223.65. The disclosure for this sale can be found here. In the last quarter, insiders acquired 334,913 shares of company stock valued at $19,083,294 and sold 13,042 shares valued at $760,526. Company insiders own 40.50% of the company’s stock.
WARNING: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/07/tesaro-tsro-receiving-somewhat-positive-news-coverage-analysis-finds.html.
Tesaro Company Profile
Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.
Receive News & Ratings for Tesaro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro and related companies with MarketBeat.com's FREE daily email newsletter.